Optimizing the management of locally advanced pancreatic cancer with a focus on induction chemotherapy: Expert opinion based on a review of current evidence

Thomas Seufferlein; Pascal Hammel; Jean Robert Delpero; Teresa Macarulla; Per Pfeiffer; Gerald W. Prager; Michele Reni; Massimo Falconi; Philip Agop Philip; Eric van Cutsem

doi:10.1016/j.ctrv.2019.05.007

journal article Jul 01, 2019

Optimizing the management of locally advanced pancreatic cancer with a focus on induction chemotherapy: Expert opinion based on a review of current evidence

Thomas Seufferlein Pascal Hammel Jean Robert Delpero Teresa Macarulla Per Pfeiffer Gerald W. Prager Michele Reni

Massimo Falconi

Philip Agop Philip Eric van Cutsem

Cancer Treatment Reviews Vol. 77 pp. 1-10 · Elsevier BV

View at Publisher Save 10.1016/j.ctrv.2019.05.007

Topics

No keywords indexed for this article. Browse by subject →

References

68

[1]

Epidemiology of pancreatic cancer

Milena Ilic, Irena Ilic

World Journal of Gastroenterology 2016 10.3748/wjg.v22.i44.9694

[2]

Ducreux "Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up" Ann Oncol (2015) 10.1093/annonc/mdv295

[3]

Malvezzi "European cancer mortality predictions for the year 2017, with focus on lung cancer" Ann Oncol (2017) 10.1093/annonc/mdx033

[4]

Ferlay "More deaths from pancreatic cancer than breast cancer in the EU by 2017" Acta Oncol (2016) 10.1080/0284186x.2016.1197419

[5]

Salami "Geographic disparities in surgical treatment recommendation patterns and survival for pancreatic adenocarcinoma" HPB (Oxford) (2017) 10.1016/j.hpb.2017.07.009

[6]

Woodmass "Physician attitudes and treatment patterns for pancreatic cancer" World J Surg Oncol (2011) 10.1186/1477-7819-9-21

[7]

Martin "Management of locally advanced pancreatic cancer" Surg Clin North Am (2016) 10.1016/j.suc.2016.07.010

[8]

Balaban "Locally advanced, unresectable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline" J Clin Oncol (2016) 10.1200/jco.2016.67.5561

[9]

NCCN. Clinical practice guidelines in oncology. Pancreatic adenocarcinoma Version 1.2019; 2019. https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf [accessed 20 March 2019].

[10]

Taieb "What treatment in 2017 for inoperable pancreatic cancers?" Ann Oncol (2017) 10.1093/annonc/mdx174

[11]

Vernerey "Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP)" Br J Cancer (2016) 10.1038/bjc.2016.212

[12]

Reni "Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma" Ann Oncol (2017) 10.1093/annonc/mdx495

[13]

Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study

B. Chauffert, F. Mornex, F. Bonnetain et al.

Annals of Oncology 2008 10.1093/annonc/mdn281

[14]

Loehrer "Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial" J Clin Oncol (2011) 10.1200/jco.2011.34.8904

[15]

Hammel "Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial" JAMA (2016) 10.1001/jama.2016.4324

[16]

Petrelli "Stereotactic body radiation therapy for locally advanced pancreatic cancer: a systematic review and pooled analysis of 19 trials" Int J Radiat Oncol Biol Phys (2017) 10.1016/j.ijrobp.2016.10.030

[17]

Goldstein "nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial" J Natl Cancer Inst (2015) 10.1093/jnci/dju413

[18]

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Thierry Conroy, Françoise Desseigne, Marc Ychou et al.

New England Journal of Medicine 2011 10.1056/nejmoa1011923

[19]

Kayahara "Surgical implication of micrometastasis for pancreatic cancer" Pancreas (2010) 10.1097/mpa.0b013e3181ce6daa

[20]

Puleo "New challenges in perioperative management of pancreatic cancer" World J Gastroenterol (2015) 10.3748/wjg.v21.i8.2281

[21]

Mukherjee "Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial" Lancet Oncol (2013) 10.1016/s1470-2045(13)70021-4

[22]

Bednar "Analysis of predictors of resection and survival in locally advanced stage III pancreatic cancer: does the nature of chemotherapy regimen influence outcomes?" Ann Surg Oncol (2017) 10.1245/s10434-016-5707-0

[23]

Gemenetzis "Survival in locally advanced pancreatic cancer after neoadjuvant therapy and surgical resection" Ann Surg (2018)

[24]

Stein "Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer" Br J Cancer (2016) 10.1038/bjc.2016.45

[25]

Fiore "Phase II study of induction chemotherapy followed by chemoradiotherapy in patients with borderline resectable and unresectable locally advanced pancreatic cancer" Sci Rep (2017) 10.1038/srep45845

[26]

Chang "Novel diagnostic and predictive biomarkers in pancreatic adenocarcinoma" Int J Mol Sci (2017) 10.3390/ijms18030667

[27]

Boone "Serum CA 19–9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma" Ann Surg Oncol (2014) 10.1245/s10434-014-3842-z

[28]

Khorana "Potentially curable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline" J Clin Oncol (2016) 10.1200/jco.2016.67.5553

[29]

Hendifar "Cachexia, and not obesity, prior to pancreatic cancer diagnosis worsens survival and is negated by chemotherapy" J Gastrointest Oncol (2018) 10.21037/jgo.2017.11.10

[30]

Dalal "Relationships among body mass index, longitudinal body composition alterations, and survival in patients with locally advanced pancreatic cancer receiving chemoradiation: a pilot study" J Pain Symptom Manage (2012) 10.1016/j.jpainsymman.2011.09.010

[31]

Naumann "Outcome after neoadjuvant chemoradiation and correlation with nutritional status in patients with locally advanced pancreatic cancer" Strahlenther Onkol (2013) 10.1007/s00066-013-0393-3

[32]

Tan "Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer" Clin Cancer Res (2009) 10.1158/1078-0432.ccr-09-1525

[33]

Mueller "Cachexia and pancreatic cancer: are there treatment options?" World J Gastroenterol (2014)

[34]

Alagappan "Albumin and neutrophil-lymphocyte ratio (NLR) predict survival in patients with pancreatic adenocarcinoma treated with SBRT" Am J Clin Oncol (2018) 10.1097/coc.0000000000000263

[35]

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

Daniel D. Von Hoff, Thomas Ervin, Francis P. Arena et al.

New England Journal of Medicine 2013 10.1056/nejmoa1304369

[36]

Ferrone "Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer" Ann Surg (2015) 10.1097/sla.0000000000000867

[37]

Verbeke "Pathology reporting of pancreatic cancer following neoadjuvant therapy: challenges and uncertainties" Cancer Treat Rev (2015) 10.1016/j.ctrv.2014.11.002

[38]

Katz "Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators" Cancer (2012) 10.1002/cncr.27636

[39]

van Veldhuisen "Added value of CA19-9 response in predicting resectability of locally advanced pancreatic cancer following induction chemotherapy" HPB (Oxford) (2018) 10.1016/j.hpb.2018.01.001

[40]

Lutz "EORTC Gastrointestinal Cancer Conference: consensus recommendations on controversial issues in the primary treatment of pancreatic cancer" Eur J Cancer (2017) 10.1016/j.ejca.2017.03.022

[41]

Value of surgical resection and timing of therapy in patients with pancreatic cancer at high risk for positive margins

Anna Torgeson, Ignacio Garrido-Laguna, Randa Tao et al.

ESMO Open 2018 10.1136/esmoopen-2017-000282

[42]

John "Redefining the R1 resection for pancreatic ductal adenocarcinoma: tumour lymph nodal burden and lymph node ratio are the only prognostic factors associated with survival" HPB (Oxford) (2013) 10.1111/hpb.12019

[43]

Alvarez-Gallego "Antitumor activity of nab-paclitaxel and gemcitabine in resectable pancreatic cancer" J Clin Oncol (2012) 10.1200/jco.2012.30.15_suppl.4040

[44]

MacKenzie "A pilot phase II multicenter study of nab-paclitaxel (Nab-P) and gemcitabine (G) as preoperative therapy for potentially resectable pancreatic cancer (PC)" J Clin Oncol (2013) 10.1200/jco.2013.31.15_suppl.4038

[45]

Pietrasz "How does chemoradiotherapy following induction FOLFIRINOX improve the results in resected borderline or locally advanced pancreatic adenocarcinoma? An AGEO-FRENCH multicentric cohort" Ann Surg Oncol (2019) 10.1245/s10434-018-6931-6

[46]

Wagner "CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma" Eur Radiol (2017) 10.1007/s00330-016-4632-8

[47]

FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis

Mustafa Suker, Berend R Beumer, Eran Sadot et al.

The Lancet Oncology 2016 10.1016/s1470-2045(16)00172-8

[48]

Hammel "Phase II LAPACT trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients with locally advanced pancreatic cancer (LAPC)" J Clin Oncol (2018) 10.1200/jco.2018.36.4_suppl.204

[49]

Reni "A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma" Eur J Cancer (2018) 10.1016/j.ejca.2018.07.007

[50]

Hackert "Locally advanced pancreatic cancer: neoadjuvant therapy with FOLFIRINOX results in resectability in 60% of the patients" Ann Surg (2016) 10.1097/sla.0000000000001850

Showing 50 of 68 references

Metrics

52

Citations

68

References

Details

Published: Jul 01, 2019
Vol/Issue: 77
Pages: 1-10
License: View

Authors

From the Institut de Cancérologie de Lorraine and Université de Lorraine (T.C.) and Centre Hospitalier Universitaire (L.C.), Nancy, Hôpital Beaujon and University Paris VII, Clichy (P.H., A.S.), Hôpital Huriez, Lille (M.H.), Centre Paul Strauss, Strasbourg (M.B.A.), Institut Paoli-Calmettes, Marseille (J.-L.R.), Centre Antoine-Lacassagne, Nice (E.F.), Hôpital Jean-Mermoz, Lyon (P.A.), Hôpital Trousseau, Tours (T.L.), Centre Hospitalier Universitaire de Saint-Eloi (E.A.) and Institut du Cancer de...

Vall d'Hebron University Hospital and Institute of Oncology, Barcelona, Spain

P

Per Pfeiffer

From the University of Texas M.D. Anderson Cancer Center, Houston (S.K., V.M.); West Cancer Center and Research Institute, OneOncology, Germantown, TN (A. Grothey); Memorial Sloan Kettering Cancer Center, New York (R.Y., A.K.); University Hospital Gasthuisberg and University of Leuven, Leuven, Belgium (E.V.C., J. Dekervel); the Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (J. Desai, C.G.); National Cancer Center Hospital East, Kashiwa, Japan (T.Y.); Hammersmith Hospital, Division of...

Karmanos Cancer Institute, Detroit, MI

E

Eric van Cutsem

Cite This Article

Thomas Seufferlein, Pascal Hammel, Jean Robert Delpero, et al. (2019). Optimizing the management of locally advanced pancreatic cancer with a focus on induction chemotherapy: Expert opinion based on a review of current evidence. Cancer Treatment Reviews, 77, 1-10. https://doi.org/10.1016/j.ctrv.2019.05.007

Optimizing the management of locally advanced pancreatic cancer with a focus on induction chemotherapy: Expert opinion based on a review of current evidence

You May Also Like